Keep An Eye On EYEG, SCYX Awaits Data In June, VBLT On The Move

(RTTNews) - Edge Therapeutics Inc.'s (EDGE) drug candidate EG-1962 has been granted Fast Track designation for the treatment of subarachnoid hemorrhage.

The company expects to begin enrollment in a pivotal phase III of EG-1962 in adults with aneurysmal subarachnoid hemorrhage in mid-2016.

EDGE closed Friday's trading at $3.31, down 2.26%.

Eyegate Pharmaceuticals Inc. (EYEG) has a couple of catalysts coming its way this quarter.

The company expects to report top-line data from its phase 1b/2a study of EGP-437 in macular edema and topline data from phase 1b/2a trial of EGP-437 for treatment of ocular inflammation and pain post cataract surgery in the second quarter 2016.

A confirmatory phase III trial of EGP-437 combination product targeting non-infectious anterior uveitis is underway - with top-line data expected in the first quarter of 2017.

EYEG closed Friday's trading at $3.14, up 3.97%.

SCYNEXIS Inc.'s (SCYX) drug candidate SCY-078 has been granted orphan drug designation for the treatment of invasive Candida infections, including candidemia by the FDA.

Two phase II studies of SCY-078 are underway - one for the treatment of vulvovaginal candidiasis (VVC) and the other for invasive candidiasis - with topline data expected in June and July 2016, respectively.

SCYX closed Friday's trading at $3.16, down 14.32%.

VBL Therapeutics' (VBLT) phase III study of VB-111 in recurrent glioblastoma multiforme, dubbed GLOBE, is underway, and interim data is expected in the first half of 2017, with full trial results expected late in 2017 or early 2018.

VBLT closed Friday's trading at $3.31, up 3.76%.